Only in Titles

           Search results for: Meningitis IgG ELISA (vaccination control)   

paperclip

#27642148   // Save this To Up

[Tick-borne encephalitis in a child in a nonendemic country: A case report].

Tick-borne encephalitis (TBE) is an arbovirus induced by tick-borne encephalitis virus (TBEV) transmitted by tick bite. The disease is rare in France (two to three cases per year) but endemic zones extend from Western Europe to the east coast of Asia (10,000-15,000 cases per year). An 8-year-old boy was admitted to our pediatric ward in Strasbourg (France) for febrile headache with diplopia. Four days after a tick bite, he declared a febrile headache together with maculopapular rash on the elbows, knees, and cheeks. Fourteen days after the outbreak of symptoms, he showed confusion, drowsiness, and binocular diplopia. Brain MRI was normal and the electroencephalogram found diffuse slow activity with no discharge. Lumbar puncture found meningitis with 92 cells (60% neutrophils, 40% lymphocytes). The diagnosis was made with specific IgM and IgG antibody isolation in the serum (Elisa). Lyme serology was negative. The evolution was slowly favorable and the child remained hospitalized for 8 days. The neurological control examination 2 weeks later was normal except for a moderate left deviation during tandem walk and left Romberg manoeuver. Meningitis or meningoencephalitis in a child must raise the diagnosis of TBE in children, even in nonendemic countries, given the recent increased incidence of TBE and the development of tourism. Recent travel in endemic areas, a history of tick bite, and a clinical course in two phases must be sought. The diagnosis is serologic and prevention is based on vaccination.

2110 related Products with: [Tick-borne encephalitis in a child in a nonendemic country: A case report].

Incu Tissue(square vessel Incu Tissue(square vessel Multi organ carcinoma tis Multi organ carcinoma tis Top five cancer tissue ar Pancreatic carcinoma and Multiple organs tumor and Tissue array of gastric d Multiple organ cancer tis Stomach adenocarcinoma wi Liver disease spectrum ti Liver carcinoma and norma

Related Pathways

paperclip

#27002793   // Save this To Up

Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes.

PNEUMOVAX™ 23, a 23-valent polysaccharide pneumococcal vaccine (PPV23), covers 65% to 91% of the isolates recovered from adult cases of invasive pneumococcal disease. Several studies have demonstrated that pneumococcal serotypes 31, 11A, 35F, 17F, 3, 16F, 19F, 15B, and 10A are associated with higher case-fatality or meningitis rates than other pneumococcal serotypes. This study (U05-PnPS-403; EudraCT: 2008-003648-12) evaluated the immune response followings administration of PPV23 for 4 of these serotypes (10A, 11A, 15B, and 17F), that are included in PPV23 but not in licensed pneumococcal conjugate vaccines. Serotype-specific IgG geometric mean concentrations (GMCs) and geometric mean fold-rises (GMFRs) for these 4 serotypes were measured by a validated enzyme-linked immunosorbent assay (ELISA) in 104 subjects >50 y of age who were enrolled in a study evaluating the safety and immunogenicity of a single-dose of PPV23. At 1 month post-vaccination, GMCs for serotypes10A, 11A, 15B and 17F were 6.5, 4.3, 14.7, and 5.1 µg/mL, respectively. GMFRs from baseline were 9.0, 4.5, 8.4, and 11.5, respectively. The percentages of subjects achieving >2-fold increases in IgG GMCs between pre-vaccination and 1 month post-vaccination were 90%, 85%, 88% and 89%, respectively. In conclusion, PPV23 induces a robust immune response in adults to pneumococcal serotypes 10A, 11A, 15B, and 17F, which have been associated with elevated case-fatality or meningitis rates.

2021 related Products with: Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes.

Primary antibody DRAK1 A Primary antibody DRAK2 A Bladder cancer tissue arr Breast cancer tissue arra Colon carcinoma antibody Colon carcinoma tissue ar Cervix carcinoma for anti Cervix cancer tissue arra Esophagus cancer tissue a Esophageal cancer tissue Kidney cancer tissue arra Kidney cancer tissue arra

Related Pathways

paperclip

#26872255   // Save this To Up

A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt.

The pattern of epidemic meningococcal disease in the African meningitis belt may be influenced by the background level of population immunity but this has been measured infrequently. A standardised enzyme-linked immunosorbent assay (ELISA) for measuring meningococcal serogroup A IgG antibodies was established at five centres within the meningitis belt. Antibody concentrations were then measured in 3930 individuals stratified by age and residence from six countries. Seroprevalence by age was used in a catalytic model to determine the force of infection. Meningococcal serogroup A IgG antibody concentrations were high in each country but showed heterogeneity across the meningitis belt. The geometric mean concentration (GMC) was highest in Ghana (9.09 μg/mL [95% CI 8.29, 9.97]) and lowest in Ethiopia (1.43 μg/mL [95% CI 1.31, 1.57]) on the margins of the belt. The force of infection was lowest in Ethiopia (λ = 0.028). Variables associated with a concentration above the putative protective level of 2 μg/mL were age, urban residence and a history of recent vaccination with a meningococcal vaccine. Prior to vaccination with the serogroup A meningococcal conjugate vaccine, meningococcal serogroup A IgG antibody concentrations were high across the African meningitis belt and yet the region remained susceptible to epidemics.

2186 related Products with: A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt.

Thermal Shaker with cooli FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu Liver cancer tissue array Liver tissue cancer tissu Hepatocellular carcinoma Multiple organ tumor tiss Interleukin-34 IL34 (N-t

Related Pathways

paperclip

#26553689   // Save this To Up

Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination.

A group A meningococcal conjugate vaccine, PsA-TT, was licensed in 2010 and was previously studied in a phase 2 clinical trial to evaluate its safety and immunogenicity in African children 12-23 months of age.

1135 related Products with: Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination.

CAR,CAR,Constitutive acti anti HSV (II) gB IgG1 (mo anti HCMV IE pp65 IgG1 (m anti HCMV gB IgG1 (monocl HIV1 integrase antibody, Anti beta3 AR Human, Poly Mouse Anti-IgG1 [+FITC] I Multiple Anti-IgG1(+FITC) CAR,Car,Constitutive andr CAR,Car,Constitutive andr Mouse AntiInfluenza B Nuc Mouse AntiInfluenza A Tar

Related Pathways

paperclip

#26553688   // Save this To Up

Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays.

PsA-TT (MenAfriVac) is a conjugated polysaccharide vaccine developed to eliminate group A meningococcal disease in Africa. Vaccination of African study participants with 1 dose of PsA-TT led to the production of anti-A polysaccharide antibodies and increased serum bactericidal activity measured using rabbit complement (rSBA). Bactericidal responses measured with human complement (hSBA) are presented here.

2769 related Products with: Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays.

Recombinant Human Interfe Rabbit Anti-APIP Apaf1 In Rabbit Anti-APIP Apaf1 In Rabbit Anti-Cell death in Rabbit Anti-Cell death in CAR,CAR,Constitutive acti Goat Anti-Human TOM1L1 SR Rabbit Anti-Human Toll In Hsp90 total Monoclonals A Blood Group Antibodies a anti B human blood group MOUSE ANTI HUMAN CD173 -

Related Pathways

paperclip

#26553687   // Save this To Up

Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.

In 2010, Africa's first preventive meningococcal mass vaccination campaign was launched using a newly developed Neisseria meningitidis group A (NmA) polysaccharide-tetanus toxoid conjugate vaccine, PsA-TT (MenAfriVac), designed specifically for the meningitis belt. Given PsA-TT's recent introduction, the duration of protection against meningococcal group A is unknown.

2540 related Products with: Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.

MultiGene Gradient therm ING1B antisense ING1B sense Interferon γ p19 INK4D AKT1 (dn) Inducible Insulin Insulin promoter factor 1 Human Insulin-like Growth Human Interferon-gamma IF Mouse Interferon gamma IF Indo 1, AM *UltraPure gra

Related Pathways

  •  
  • No related Items
paperclip

#26553684   // Save this To Up

Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.

Mass vaccination campaigns of the population aged 1-29 years with 1 dose of group A meningococcal (MenA) conjugate vaccine (PsA-TT, MenAfriVac) in African meningitis belt countries has resulted in the near-disappearance of MenA. The vaccine was tested in clinical trials in Africa and in India and found to be safe and highly immunogenic compared with the group A component of the licensed quadrivalent polysaccharide vaccine (PsACWY). Antibody persistence in Africa and in India was investigated.

2957 related Products with: Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.

INPP5F antibody Source Ra Interferon alpha-8 antibo Interferon alpha-6 antibo V-ATPase H antibody Sourc ORC2 antibody Source Rabb interleukin 17 receptor C V-ATPase C2 antibody Sour ATPase beta3(Na+ K+) anti TGF beta induced factor 2 Primary antibody Ataxin ATIC antibody Source Rabb INPP1 antibody Source Rab

Related Pathways

  •  
  • No related Items
paperclip

#26553683   // Save this To Up

Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.

Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in healthy African toddlers was investigated.

1893 related Products with: Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.

Interferon-a Receptor Typ Integrin β1 (CD29) Antib LPAM-1(Integrin α4, CD49 α-Internexin Antibody So Atherosclerosis (Human) A Atherosclerosis (Mouse) A MAPK3 & ATF2 Protein Prot ATF4 & CREBBP Protein Pro ATF4 & FOS Protein Protei ATF4 & JUN Protein Protei to Viral Interleukin-6 ( Adeno Associated Virus (A

Related Pathways

paperclip

#23741368   // Save this To Up

Sustained protection in mice immunized with fractional doses of Salmonella Enteritidis core and O polysaccharide-flagellin glycoconjugates.

Non-typhoidal Salmonella (NTS) serovars S. Enteritidis and S. Typhimurium are a major cause of invasive bacterial disease (e.g., bacteremia, meningitis) in infants and young children in sub-Saharan Africa and also occasionally cause invasive disease in highly susceptible hosts (young infants, the elderly, and immunocompromised subjects) in industrialized countries. No licensed vaccines exist against human NTS infections. NTS core and O polysaccharide (COPS) and FliC (Phase 1 flagellin subunits) each constitute protective antigens in murine models. S. Enteritidis COPS conjugated to FliC represents a promising vaccine approach that elicits binding and opsonophagocytic antibodies and protects mice against lethal challenge with virulent S. Enteritidis. We examined the protective efficacy of fractional dosages of S. Enteritidis COPS:FliC conjugate vaccines in mice, and also established that protection can be passively transferred to naïve mice by administering sera from mice immunized with conjugate. Mice were immunized with three doses of either 10 µg, 2.5 µg (full dose), 0.25 µg, or 0.025 µg S. Enteritidis COPS:FliC conjugate at 28 day intervals. Antibody titers to COPS and FliC measured by ELISA fell consonant with progressively smaller vaccine dosage levels; anti-FliC IgG responses remained robust at fractional dosages for which anti-COPS serum IgG titers were decreased. Nevertheless, >90% protection against intraperitoneal challenge was observed in mice immunized with fractional dosages of conjugate that elicited diminished titers to both FliC and COPS. Passive transfer of immune sera from mice immunized with the highest dose of COPS:FliC to naïve mice was also protective, demonstrating the role of antibodies in mediating protection. These results provide important insights regarding the potency of Salmonella glycoconjugate vaccines that use flagellin as a carrier protein.

2910 related Products with: Sustained protection in mice immunized with fractional doses of Salmonella Enteritidis core and O polysaccharide-flagellin glycoconjugates.

Multi organ carcinoma tis Multi organ carcinoma tis Pancreatic carcinoma and Multiple organs tumor and Multiple organ cancer tis Ovarian cancer tissue arr Ovary cancer tissue array Ovary cancer tissue array Ovary cancer tissue array Ovary serous papillary ad Multiple organ cancer and Multiple organ tumor and

Related Pathways

paperclip

#21679737   // Save this To Up

Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii.

Acinetobacter baumannii produces different types of infections including pneumonia, meningitis, and bloodstream infections. The optimal treatment of these infections has been complicated by the global emergence of multidrug resistant strains, requiring the development of novel approaches for treatment and prevention. Outer membrane vesicles are outpouchings of the bacterial outer membrane that are secreted from numerous pathogenic Gram-negative bacteria. In the present study, we describe the isolation of outer membrane vesicles from A. baumannii and their use as a vaccine in a mouse model of disseminated sepsis. Immunization produced a robust antibody response against multiple bacterial antigens which consisted of antigen-specific IgG and IgM. In addition, both IgG1 and IgG2c subtypes were produced by immunization. Immunized mice had lower tissue bacterial loads and lower serum levels of the pro-inflammatory cytokines IL-6 and IL-1β post-infection compared to control mice. Importantly, vaccination protected mice from challenge with the ATCC 19606 strain and provided protection against two clinical isolates, including a pan-resistant strain. These results indicate that vaccination with outer membrane vesicles may be a viable strategy for preventing A. baumannii infection.

2489 related Products with: Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii.

Rabbit Anti-ompF(putative Epithelial Membrane Anti Epithelial Membrane Anti Epithelial Membrane Anti Biotin-Conjugated Anti-Cy Biotin-Conjugated Anti-Cy Biotin-Conjugated Anti-Cy Biotin-Conjugated Anti-Cy Biotin-Conjugated Anti-Cy Biotin-Conjugated Anti-Cy Biotin-Conjugated Anti-Cy Biotin-Conjugated Anti-Cy

Related Pathways